Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a significant increase in net profit despite a decline in revenue, demonstrating strong operational capabilities and strategic execution [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.126 billion yuan, a year-on-year decrease of 20.21% - The net profit attributable to shareholders reached 1.282 billion yuan, a year-on-year increase of 138.44% [1]. Business Structure - The traditional Chinese medicine segment remains the core business, generating sales revenue of 686 million yuan, accounting for 60.90% of total revenue - The chemical drugs, chain pharmacy wholesale and retail, and health industry segments contributed sales revenues of 143 million yuan, 187 million yuan, and 83 million yuan, representing 12.73%, 16.59%, and 7.39% of total revenue, respectively [1]. Strategic Initiatives - The company is actively reforming its marketing system in the traditional Chinese medicine segment, having completed the marketing restructuring of 22 products and adjusted pricing policies for over 50 products - The company has made significant progress in its Chinese medicine formula granule business, obtaining 525 registration certificates for market access [2]. - A plan to issue convertible bonds to raise 134 million yuan for capital increase in its subsidiary, aimed at constructing a project for Chinese medicine formula granules with an annual production capacity of 2,000 tons [2]. Market Trends - The recovery of the consumer market is expected to accelerate the sales of consumer-oriented traditional Chinese medicine - Long-term growth is supported by an aging population and increasing health awareness among residents, providing a solid foundation for the industry [3]. Operational Efficiency - The company has optimized operational efficiency and adjusted regional layouts by closing some chain pharmacy stores, while enhancing brand management and deepening industry chain collaboration - The chain pharmacy business added 73,000 new members during the reporting period [3]. Asset Management - As of June 30, 2025, the company reported total assets of 34.151 billion yuan, a 3.48% increase from the beginning of the year, and net assets of 29.960 billion yuan, a 3.21% increase - The asset-liability ratio stands at 11.54%, indicating a low level within the industry [4].

董事长：吴海明 二〇二五年八月二十一日 公司董事会、监事会及董事、监事、高级管理人员保证半年度报 告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 公司负责人吴海明、主管会计工作负责人张斌及会计机构负责人 （会计主管人员）顾叶倩声明：保证本半年度报告中财务报告的真实、 准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 浙江震元股份有限公司 浙江震元股份有限公司 | 二、报告期内公开披露过的所有公司文件的正本及公告的原稿。 | | | | --- | --- | --- | | | | 释 义 | | 释义项 指 | | 释义内容 | | 本公司/公司/ | | | | 指 | | 浙江震元股份有限公司 | | 浙江震元 | | | | 震元健康集团 | | 指 绍兴震元健康产业集团有限公司，为公司控股股东。 | | | | 绍兴市人民政府国有资产监督管理委员会，为公司实际 | | 绍兴市国资委 | | 指 | | | | 控制人。 | | 震元制药 指 | | 浙江震元制药有限公司，为公司全资子公司。 | | 震元生物 指 | | 浙江震元生物科技有限 ...